Medigen Vaccine Biologics - Asset Resilience Ratio
Medigen Vaccine Biologics (6547) has an Asset Resilience Ratio of 37.48% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Medigen Vaccine Biologics (6547) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2025)
This chart shows how Medigen Vaccine Biologics's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Medigen Vaccine Biologics balance sheet assets.
Liquid Assets Composition Over Time
This chart breaks down Medigen Vaccine Biologics's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Medigen Vaccine Biologics total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$1.78 Billion | 37.48% |
| Total Liquid Assets | NT$1.78 Billion | 37.48% |
Asset Resilience Insights
- Very High Liquidity: Medigen Vaccine Biologics maintains exceptional liquid asset reserves at 37.48% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Medigen Vaccine Biologics Industry Peers by Asset Resilience Ratio
Compare Medigen Vaccine Biologics's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653 |
Biotechnology | 1.69% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.12% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 23.94% |
|
ChemPartner PharmaTech Co Ltd
SHE:300149 |
Biotechnology | 1.67% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Yantai Zhenghai Bio-Tech Co Ltd
SHE:300653 |
Biotechnology | 59.25% |
Annual Asset Resilience Ratio for Medigen Vaccine Biologics (2014–2025)
The table below shows the annual Asset Resilience Ratio data for Medigen Vaccine Biologics.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 30.11% | NT$1.18 Billion ≈ $37.32 Million |
NT$3.93 Billion ≈ $123.94 Million |
+2.61pp |
| 2024-12-31 | 27.50% | NT$1.20 Billion ≈ $37.81 Million |
NT$4.36 Billion ≈ $137.49 Million |
-11.96pp |
| 2023-12-31 | 39.46% | NT$2.40 Billion ≈ $75.75 Million |
NT$6.09 Billion ≈ $191.95 Million |
-1.81pp |
| 2022-12-31 | 41.28% | NT$3.03 Billion ≈ $95.55 Million |
NT$7.35 Billion ≈ $231.49 Million |
+25.18pp |
| 2021-12-31 | 16.10% | NT$853.10 Million ≈ $26.88 Million |
NT$5.30 Billion ≈ $166.95 Million |
+14.58pp |
| 2020-12-31 | 1.52% | NT$53.17 Million ≈ $1.68 Million |
NT$3.49 Billion ≈ $109.98 Million |
-0.81pp |
| 2019-12-31 | 2.34% | NT$53.23 Million ≈ $1.68 Million |
NT$2.28 Billion ≈ $71.74 Million |
-20.68pp |
| 2018-12-31 | 23.02% | NT$502.52 Million ≈ $15.83 Million |
NT$2.18 Billion ≈ $68.78 Million |
+22.88pp |
| 2017-12-31 | 0.14% | NT$2.97 Million ≈ $93.57K |
NT$2.14 Billion ≈ $67.31 Million |
-1.15pp |
| 2016-12-31 | 1.29% | NT$23.46 Million ≈ $739.02K |
NT$1.82 Billion ≈ $57.26 Million |
+0.06pp |
| 2015-12-31 | 1.23% | NT$20.32 Million ≈ $640.19K |
NT$1.65 Billion ≈ $52.09 Million |
-32.62pp |
| 2014-12-31 | 33.85% | NT$411.20 Million ≈ $12.96 Million |
NT$1.21 Billion ≈ $38.27 Million |
-- |
About Medigen Vaccine Biologics
Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for th… Read more